OMIC Multiplikator Forward P/S Singular Genomics
Sequencing system sales depend on research institute grants and biomolecule analysis precision, which impacts the forward P/S multiple, where the current level is 18.80. Singular Genomics Systems (OMIC) revenues are based on the supply of equipment and consumables for oncology. Current workforce optimization and a focus on clinical trials are stabilizing quotes, helping investors recognize asset overheating in a timely manner and assess its margin of safety.
Ringkesan rincian data analitis Singular Genomics Corp (OMIC)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi pasar:
- statistik nilai buku emiten:
- data utang lan likuiditas:
Utang marang Ekuitas Singular Genomics Systems|OMIC - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Singular Genomics Systems|OMIC - Gunggung kewajiban utang perusahaan|Utang-utang marang kapitalisasi buku Singular Genomics Corp|OMIC - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Singular Genomics|Indikator likuiditas cepet singulargenomics.com
- data bathi bisnis lan rasio investasi:
OMIC - Bathi pungkasan|Bathi sing dikarepake Singular Genomics Systems|OMIC - Periode bali modal bisnis|Prakiraan rega marang bathi Singular Genomics Systems Inc|OMIC - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Singular Genomics Corp|OMIC - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Singular Genomics|OMIC - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan singulargenomics.com|OMIC - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Singular Genomics Systems
- indikator dodolan lan pendapatan:
Analisis komprehensif perusahaan:Singular Genomics OMIC
Stable component supplies for Singular Genomics Systems (OMIC) strengthen its operational base, which is reflected in the organization's forward P/S ratio. This indicator compares current market capitalization with expected revenue, transforming static quarterly forecasts into a dynamic valuation curve that allows investors to promptly recognize asset overheating and determine the business's fundamental value relative to its future earnings.
Pesaing Singular Genomics Systems (OMIC)
Multiplikator Forward P/S TEM (Tempus AI, Inc.)|Prakiraan rega marang pendapatan Qiagen NV|Ionis Pharma - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Repligen Inc.|Avidity Biosciences (RNA) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan CRSP|Rasio rega marang prakiraan pendapatan GeneDx|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ultragenyx Pharmaceutical Inc. RARE|Rasio rega marang prakiraan pendapatan Beam Therapeutics Corp (BEAM)|Multiplikator forward rega marang pendapatan Sarepta Corp SRPT|Multiplikator Forward P/S TWST (Twist Bioscience)|Rasio kapitalisasi marang dodolan sing dikarepake 10xgenomics.com (TXG)|Intellia Therapeutics, Inc. - Multiplikator Forward P/S|Stoke Therapeutics Inc (STOK) - Multiplikator forward rega marang pendapatan|BioLife Corp (BLFS) - Rasio rega marang prakiraan pendapatan|WVE - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan MAZE|SION: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Prime Medicine (PRME)|Rasio kapitalisasi marang dodolan sing dikarepake Taysha Gene Therapies Inc|uniQure Corp - Multiplikator forward rega marang pendapatan|MeiraGTx Corp (MGTX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RGNX - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake solidbio.com SLDB|OCGN (Ocugen) - Multiplikator forward rega marang pendapatan|PACB: Rasio rega marang pendapatan sing dikarepake|BNTC (Benitec) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Design Corp DSGN|Rasio rega marang prakiraan pendapatan Rocket Pharmaceuticals (RCKT)|Multiplikator forward rega marang pendapatan 4dmoleculartherapeutics.com FDMT|Rasio rega marang prakiraan pendapatan Lexeo Therapeutics, Inc. LXEO|Rasio kapitalisasi marang dodolan sing dikarepake Korro Bio Inc. (KRRO)|EDIT - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Silence Therapeutics Corp|proqr.com (PRQR) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Codexis|SGMO (Sangamo Therapeutics, Inc.) - Multiplikator Forward P/S|Nautilus Biotechnology Inc (NAUT) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S MGX|Multiplikator forward rega marang pendapatan Precision BioSciences Inc. DTIL|Multiplikator Forward P/S GBIO (Generation Bio)|BOLD: Kapitalisasi marang prakiraan pendapatan|XCUR - Rasio rega marang prakiraan pendapatan|IMNN (Imunon, Inc.) - Kapitalisasi marang prakiraan pendapatan|PHIO: Multiplikator Forward P/S|Mustang Bio (MBIO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan TransCode Therapeutics Inc.|Bionano (BNGO) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S APDN|Rasio kapitalisasi marang dodolan sing dikarepake bluebird bio Inc.|Rasio rega marang prakiraan pendapatan ImmunoPrecise Antibodies Ltd. IPA|OMGA: Kapitalisasi marang prakiraan pendapatan|Regulus Therapeutics - Multiplikator Forward P/S|Prakiraan rega marang pendapatan syros.com (SYRS)|TBIO (Telesis Bio) - Multiplikator forward rega marang pendapatan|TRACON Pharmaceuticals Inc. (TCON) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Unity Bio
